Are VSTM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies VSTM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / VSTM / insiders

AMPH (72) RAPP (30) SNDX (17) SLN (44) ⌘ Pro Terminal →

Verastem Inc. (VSTM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.59 -1.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.54

Verastem Inc. (VSTM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VSTM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Verastem Inc. (NASDAQ: VSTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.59 (-1.64% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VSTM ranks #562 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VSTM compare to AMPH and RAPP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AMPH (Amphastar Pharmaceuticals Inc.) holds a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VSTM?

▼

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.54 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY VSTM SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (44% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 83% of 52W Range • RSI-14 at 61.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.45+25.4% Next Q

Q2 (-2Q)

Grade E$9.34+8.1% Next Q

Q3 (-1Q)

Grade E$10.10-5% Next Q

Current

Grade D-$9.59-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VSTM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.27) and Max Pain ($10.07) forces dealer call-delta covering toward $11.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VSTM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VSTM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VSTM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

✓Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +61.18%▲ ASCENDING CHANNEL

2026-11-03O $9.66H $9.75L $9.59C $9.59VOL 2.41M

RES: $10.39SUP: $7.01SMA50: $8.27SMA200: $6.20

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VSTM Butterfly Map → + Track VSTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #562 of 1016 ⚔️ AMPH vs VSTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VSTM vs. AMPH, RAPP, SNDX, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #562 by composite RQD confidence (36/100, grade D-) and #335 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with VSTM at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VSTM ACTIVE Verastem Inc.	D-	36/100	—	—	-35.0%	-1.64%	$1.18B	Benchmark Subject
AMPH Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	-2.49%	$1.18B	/amph-vs-vstm →
RAPP Rapport Therapeutics Inc.	E	30/100	—	—	-22.9%	+0.32%	$1.20B	/rapp-vs-vstm →
SNDX Syndax Pharmaceuticals Inc.	E	17/100	—	—	-35.0%	-4.03%	$1.22B	/sndx-vs-vstm →
SLN Silence Therapeutics Plc American Depository Share	D	44/100	—	61.5%	-35.0%	+0.05%	$1.23B	/sln-vs-vstm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001526119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M , and -88.0% cumulative change since FY2023) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.9M	-$209.5M	-$137.5M	-$137.5M	$246.4M	—
FY2024 (FY)	2024-12-31	$10.0M	-$130.6M	-$104.8M	-$104.8M	$101.5M	—
FY2023 (FY)	2023-12-31	$257.8M	-$87.4M	-$86.5M	-$86.5M	—	—

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VSTM compare to AMPH and RAPP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.59 (-1.64% on volume of 2,112,810 shares), positioning the stock +15.96% above its 50-day simple moving average ($8.27) and +54.68% above its 200-day simple moving average ($6.20). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 83.4% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.39 to $10.79).

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VSTM — Verastem Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:23Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

VSTM scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (4 / 20): Per the RQD rating, ROIC is -35% and FCF yield is -11.72%. This is the weakest pillar and indicates the business is currently consuming cash rather than generating it.
Whale 13F Flow (16 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning.
Insider Conviction (3 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low. This is a weak signal of insider confidence and a valuation consideration an investor should weigh.
Macro Regime Fit (8 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. The stock is assessed as moving in line with the broader market, offering neither a defensive profile nor a clear macro tailwind in the source data.
Forensic Balance Sheet (5 / 20): Per the RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings signal balance sheet vulnerability, a central risk for any prospective investor.

Taken together, the rating suggests the primary upside driver is institutional interest and the primary risk is cash burn and balance sheet strength. The valuation tradeoff is that the share price has moved sharply within its 52-week range, while the underlying cash metrics remain negative.

2. Business Model, Unit Margins & SEC Financial Trajectory

Verastem Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

Revenue grew from — in FY 2023 to $30.9M in FY 2025 while losses widened in each period, with FY 2025 net income at -$209.5M. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both indicating financial stress. Debt/Equity is 0. Cash was $205.0M at the latest reported period.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after strong trial data. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield -11.72%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $3.43 – $10.82 52-week range.
🐻 Primary Bear Case: With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and cash burn are the dominant risks. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VSTM carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: What is the cash runway given $205.0M in cash against FY 2025 free cash flow of -$137.5M, and how does the $250 Million offering change that picture?
Key Question #2: What trial results drove the Mizuho price target increase, and what is the trial's regulatory status?
Key Question #3: How sensitive is VSTM's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?

VSTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Verastem Inc. (VSTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VSTM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago

Verastem, Inc. (VSTM) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 23h ago

Verastem, Inc. (VSTM) stock price, news, quote and history

Yahoo Finance UK report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Mizuho raises Verastem stock price target on strong trial data

Investing.com report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Business Wire report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Zacks Investment Research • 1d ago

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

Zacks Investment Research report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Verastem (VSTM) Stock Forum and Discussion

Moomoo report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM)

Seeking Alpha report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Verastem Oncology (VSTM) Shares Surge 20% Premarket on CEO Change and $250M Stock Offering

GuruFocus report covering Verastem Inc. (VSTM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VSTM Bull vs. Bear Conversation Board — What's Your Call at $9.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VSTM 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $11.21 (+15.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after stro

Institutional accumulation and options positioning score 16/20 in the RQD rating, and analysts are cited as expecting upside after strong trial data.. When you look under the hood at VSTM, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $10.82. My 12M target is $11.21.

ArenaChamp_24 🐂 BULL

@SiliconVal_Bull Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.75 and keeping dry powder in case we test $9.07.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $8.09 (-17.0%)

Spot @ $9.75

With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and ca

Careful chasing VSTM at $9.75. With an Altman Z of 0.2, Piotroski F of 3/9, FY 2025 net loss of -$209.5M, and a $250 Million equity offering, the balance sheet and cash burn are the dominant risks.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.09 on multiple compression.